Browsing by Author "Hammerman, Peter S."

Now showing items 1-14 of 14

    • Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors 

      Akbay, E; Koyama, S.; Carretero, J.; Altabef, A.; Tchaicha, J. H.; Christensen, Camilla Laulund; Mikse, O. R.; Cherniack, Andrew David; Beauchamp, Ellen Monica; Pugh, T; Wilkerson, M. D.; Fecci, P; Butaney, M.; Reibel, J. B.; Soucheray, M.; Cohoon, T. J.; Janne, Pasi Antero; Meyerson, Matthew Langer; Hayes, D. N.; Shapiro, Geoffrey Ira; Shimamura, T; Sholl, Lynette Marie; Rodig, Scott J.; Freeman, Gordon James; Hammerman, Peter Seth; Dranoff, G; Wong, Kwok-Kin (American Association for Cancer Research (AACR), 2013)
      The success in lung cancer therapy with Programmed Death (PD)-1 blockade suggests that immune escape mechanisms contribute to lung tumor pathogenesis. We identified a correlation between Epidermal Growth Factor Receptor ...

    • Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints 

      Koyama, Shohei; Akbay, Esra A.; Li, Yvonne Y.; Herter-Sprie, Grit S.; Buczkowski, Kevin A.; Richards, William G.; Gandhi, Leena; Redig, Amanda J.; Rodig, Scott J.; Asahina, Hajime; Jones, Robert E.; Kulkarni, Meghana M.; Kuraguchi, Mari; Palakurthi, Sangeetha; Fecci, Peter E.; Johnson, Bruce E.; Janne, Pasi A.; Engelman, Jeffrey A.; Gangadharan, Sidharta P.; Costa, Daniel B.; Freeman, Gordon J.; Bueno, Raphael; Hodi, F. Stephen; Dranoff, Glenn; Wong, Kwok-Kin; Hammerman, Peter S. (Nature Publishing Group, 2016)
      Despite compelling antitumour activity of antibodies targeting the programmed death 1 (PD-1): programmed death ligand 1 (PD-L1) immune checkpoint in lung cancer, resistance to these therapies has increasingly been observed. ...

    • Challenges in EGFRvIII Detection in Head and Neck Squamous Cell Carcinoma 

      Wheeler, Sarah E.; Egloff, Ann Marie; Wang, Lin; James, C. David; Hammerman, Peter S.; Grandis, Jennifer R. (Public Library of Science, 2015)
      Objective: Head and neck squamous cell carcinoma (HNSCC) accounts for more than 5% of all cancers worldwide. The mortality rate of HNSCC has remained unchanged (approximately 50%) over the last few decades. Ubiquitous ...

    • Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer 

      Terai, Hideki; Tan, Li; Beauchamp, Ellen M.; Hatcher, John M.; Liu, Qingsong; Meyerson, Matthew; Gray, Nathanael S.; Hammerman, Peter S. (American Chemical Society, 2015)
      Despite advances in precision medicine approaches over the past decade, the majority of nonsmall cell lung cancers (NSCLCs) are refractory to treatment with targeted small molecule inhibitors. Previous work has identified ...

    • Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas 

      Campbell, Joshua D.; Alexandrov, Anton; Kim, Jaegil; Wala, Jeremiah; Berger, Alice H.; Pedamallu, Chandra Sekhar; Shukla, Sachet A.; Guo, Guangwu; Brooks, Angela N.; Murray, Bradley A.; Imielinski, Marcin; Hu, Xin; Ling, Shiyun; Akbani, Rehan; Rosenberg, Mara; Cibulskis, Carrie; Ramachandran, Aruna; Collisson, Eric A.; Kwiatkowski, David J.; Lawrence, Michael S.; Weinstein, John N.; Verhaak, Roel G. W.; Wu, Catherine J.; Hammerman, Peter S.; Cherniack, Andrew D.; Getz, Gad; Artyomov, Maxim N.; Schreiber, Robert; Govindan, Ramaswamy; Meyerson, Matthew (2016)
      To compare lung adenocarcinoma (ADC) and lung squamous cell carcinoma (SqCC) and to identify new drivers of lung carcinogenesis, we examined exome sequences and copy number profiles of 660 lung ADC and 484 lung SqCC ...

    • Fine needle aspirate flow cytometric phenotyping characterizes immunosuppressive nature of the mesothelioma microenvironment 

      Lizotte, Patrick H.; Jones, Robert E.; Keogh, Lauren; Ivanova, Elena; Liu, Hongye; Awad, Mark M.; Hammerman, Peter S.; Gill, Ritu R.; Richards, William G.; Barbie, David A.; Bass, Adam J.; Bueno, Raphael; English, Jessie M.; Bittinger, Mark; Wong, Kwok-Kin (Nature Publishing Group, 2016)
      With the emergence of checkpoint blockade and other immunotherapeutic drugs, and the growing adoption of smaller, more flexible adaptive clinical trial designs, there is an unmet need to develop diagnostics that can rapidly ...

    • A genetic basis for the variation in the vulnerability of cancer to DNA damage 

      Yard, Brian D.; Adams, Drew J.; Chie, Eui Kyu; Tamayo, Pablo; Battaglia, Jessica S.; Gopal, Priyanka; Rogacki, Kevin; Pearson, Bradley E.; Phillips, James; Raymond, Daniel P.; Pennell, Nathan A.; Almeida, Francisco; Cheah, Jaime H.; Clemons, Paul A.; Shamji, Alykhan; Peacock, Craig D.; Schreiber, Stuart L.; Hammerman, Peter S.; Abazeed, Mohamed E. (Nature Publishing Group, 2016)
      Radiotherapy is not currently informed by the genetic composition of an individual patient's tumour. To identify genetic features regulating survival after DNA damage, here we conduct large-scale profiling of cellular ...

    • The impact of the MYB-NFIB fusion proto-oncogene in vivo 

      Mikse, Oliver R.; Tchaicha, Jeremy H.; Akbay, Esra A.; Chen, Liang; Bronson, Roderick T.; Hammerman, Peter S.; Wong, Kwok-Kin (Impact Journals LLC, 2016)
      Recurrent fusion of the v-myb avian myelobastosis viral oncogene homolog (MYB) and nuclear factor I/B (NFIB) generates the MYB-NFIB transcription factor, which has been detected in a high percentage of individuals with ...

    • Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer 

      Dutt, Amit; Ramos, Alex H.; Hammerman, Peter Seth; Mermel, Craig Harold; Cho, Jeonghee; Sharifnia, Tanaz; Chande, Ajit; Tanaka, Kumiko Elisa; Stransky, Nicolas; Greulich, Heidi E.; Gray, Nathanael Schiander; Meyerson, Matthew Langer (Public Library of Science, 2011)
      Background: Squamous cell lung carcinomas account for approximately 25% of new lung carcinoma cases and 40,000 deaths per year in the United States. Although there are multiple genomically targeted therapies for lung ...

    • Integrated RNA and DNA sequencing improves mutation detection in low purity tumors 

      Wilkerson, Matthew D.; Cabanski, Christopher R.; Sun, Wei; Hoadley, Katherine A.; Walter, Vonn; Mose, Lisle E.; Troester, Melissa A.; Hammerman, Peter S.; Parker, Joel S.; Perou, Charles M.; Hayes, D. Neil (Oxford University Press, 2014)
      Identifying somatic mutations is critical for cancer genome characterization and for prioritizing patient treatment. DNA whole exome sequencing (DNA-WES) is currently the most popular technology; however, this yields low ...

    • Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC 

      Tchaicha, J. H.; Akbay, E; Altabef, A.; Mikse, O. R.; Kikuchi, E.; Rhee, K.; Liao, R; Bronson, Roderick Terry; Sholl, Lynette Marie; Meyerson, Matthew Langer; Hammerman, Peter Seth; Wong, Kwok-Kin (American Association for Cancer Research (AACR), 2014)
      Somatic mutations in Fibroblast Growth Factor Receptor 2 (FGFR2) are present in 4-5% of patients diagnosed with non-small cell lung cancer (NSCLC). Amplification and mutations in FGFR genes have been identified in patients ...

    • Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation 

      Van Allen, Eliezer Mendel; Golay, H. G.; Liu, Yan; Koyama, S.; Wong, Kwok-Kin; Taylor-Weiner, Amaro; Giannakis, Marios; Harden, M.; Rojas-Rudilla, V.; Chevalier, A.; Thai, T.; Lydon, C.; Mach, S.; Wong, J. A.; Rabin, A. R.; Helmkamp, J.; Sholl, Lynette Marie; Carter, Scott Lambert; Oxnard, Geoffrey Raymond; Janne, Pasi Antero; Getz, Gad A; Lindeman, Neal I.; Hammerman, Peter Seth; Garraway, Levi Alexander; Hodi, Frank Stephen; Rodig, Scott J.; Dranoff, G; Wong, Kwok-Kin; Barbie, David Allen (American Association for Cancer Research (AACR), 2015)
      PD-1 immune checkpoint blockade occasionally results in durable clinical responses in advanced metastatic cancers. However, mechanism-based predictors of response to this immunotherapy remain incompletely characterized. ...

    • MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression 

      Awad, Mark Magdi; Oxnard, Geoffrey Raymond; Jackman, David M; Savukoski, Daniel O.; Hall, Dimity; Shivdasani, Priyanka; Heng, Jennifer C.; Dahlberg, Suzanne Eleanor; Janne, Pasi Antero; Verma, Suman; Christensen, James; Hammerman, Peter Seth; Sholl, Lynette Marie (American Society of Clinical Oncology (ASCO), 2016)
      Purpose Non–small-cell lung cancers (NSCLCs) harboring mutations in MET exon 14 and its flanking introns may respond to c-Met inhibitors. We sought to describe the clinical, pathologic, and genomic characteristics of ...

    • Mutational heterogeneity in cancer and the search for new cancer genes 

      Lawrence, Michael S.; Stojanov, Petar; Polak, Paz; Kryukov, Gregory V.; Cibulskis, Kristian; Sivachenko, Andrey; Carter, Scott L.; Stewart, Chip; Mermel, Craig H.; Roberts, Steven A.; Kiezun, Adam; Hammerman, Peter S.; McKenna, Aaron; Drier, Yotam; Zou, Lihua; Ramos, Alex H.; Pugh, Trevor J.; Stransky, Nicolas; Helman, Elena; Kim, Jaegil; Sougnez, Carrie; Ambrogio, Lauren; Nickerson, Elizabeth; Shefler, Erica; Cortés, Maria L.; Auclair, Daniel; Saksena, Gordon; Voet, Douglas; Noble, Michael; DiCara, Daniel; Lin, Pei; Lichtenstein, Lee; Heiman, David I.; Fennell, Timothy; Imielinski, Marcin; Hernandez, Bryan; Hodis, Eran; Baca, Sylvan; Dulak, Austin M.; Lohr, Jens; Landau, Dan-Avi; Wu, Catherine J.; Melendez-Zajgla, Jorge; Hidalgo-Miranda, Alfredo; Koren, Amnon; McCarroll, Steven A.; Mora, Jaume; Crompton, Brian; Onofrio, Robert; Parkin, Melissa; Winckler, Wendy; Ardlie, Kristin; Gabriel, Stacey B.; Roberts, Charles W. M.; Biegel, Jaclyn A.; Stegmaier, Kimberly; Bass, Adam J.; Garraway, Levi A.; Meyerson, Matthew; Golub, Todd R.; Gordenin, Dmitry A.; Sunyaev, Shamil; Lander, Eric S.; Getz, Gad (2014)
      Major international projects are now underway aimed at creating a comprehensive catalog of all genes responsible for the initiation and progression of cancer. These studies involve sequencing of matched tumor–normal samples ...